Breaking News Instant updates and real-time market news.

AMGN

Amgen

$174.63

0.9 (0.52%)

, NVS

Novartis

$77.15

-0.45 (-0.58%)

20:54
05/17/18
05/17
20:54
05/17/18
20:54

Amgen's Aimovig launch in migraine should beat expectations, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $190 price target on Amgen (AMGN) after today's FDA approval of Aimovig in migraine. The analyst notes that this marks the first anti-CGRP therapy approval in what is expected to be a crowded space, adding that Amgen and its partner Novartis (NVS) have "effectively capitalized on their first-mover advantage." The analyst says the smart pricing for the product should allow this launch to "beat expectations".

AMGN

Amgen

$174.63

0.9 (0.52%)

NVS

Novartis

$77.15

-0.45 (-0.58%)

  • 17

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

AMGN Amgen
$174.63

0.9 (0.52%)

04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
05/15/18
MZHO
05/15/18
NO CHANGE
Target $200
MZHO
Buy
Amgen buyback activity could buoy shares, says Mizuho
Mizuho analyst Salim Syed says that for Amgen to buy back the $2B-$4B of its own stock this quarter, as it said it would do, it would have to make up 5%-11% of daily volume traded every day in the current quarter. The analyst is "not fully convinced this math has been entirely digested by the Street." This could potentially act as a buoy for the stock this quarter, Syed tells investors in a research note. The analyst keeps a Buy rating on the shares with a $200 price target.
05/16/18
MSCO
05/16/18
NO CHANGE
Target $200
MSCO
Overweight
Epogen biosimilar should have little impact on Amgen, says Morgan Stanley
After the FDA approved Retacrit, Pfizer's (PFE) biosimilar version of Amgen's (AMGN) Epogen, Morgan Stanley analyst Matthew Harrison said he does not see significant impact to his forecasts due to the news, noting that Amgen has already discounted Epogen net selling price significantly to secure an extended supply agreement with DaVita (DVA). Amgen renegotiated the supply agreement in early 2017 and the vast majority of Epogen volume is from DaVita, added Harrison, who maintains an Overweight rating and $200 price target on Amgen shares.
NVS Novartis
$77.15

-0.45 (-0.58%)

04/18/18
BERN
04/18/18
NO CHANGE
BERN
Spark Therapeutics, uniQure may be potential takeout targets, says Bernstein
Following AveXis (AVXS) acquisition by Novartis (NVS), Bernstein analyst Vincent Chen says the potential next target should have a strong portfolio fit and innovation-oriented scientifically-minded management teams likely comfortable with the technology platform. For acquisition targets, the analyst sees two flavors, namely late stage more de-risked gene therapy companies, for which Spark (ONCE) comes to mind, and less costly but riskier earlier-stage platforms, for which uniQure (QURE), Voyager (VYGR) and REGENXBIO (RGNX) come to mind.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
05/01/18
RBCM
05/01/18
NO CHANGE
RBCM
Sector Perform
Regeneron's Eylea faces strong competition from brolucizumab, says RBC Capital
RBC Capital analyst Kennen MacKay says yesterday's phase 3 presentation of data from Novartis (NVS) regarding the prospects of brolucizumab in wet age-related macular degeneration suggests that the treatment is strongly positioned vs. Regeneron's (REGN) Eylea. MacKay adds that Novartis intends to submit the Biologics License Applications for brolucizumab in December of this year, with expected launch in the second half of 2019. The analyst keeps his Sector Perform rating on Regeneron.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$319.05

10.55 (3.42%)

11:21
08/21/18
08/21
11:21
08/21/18
11:21
Periodicals
Tesla had to rework over 4,300 Model 3s amid hitting 5,000 target, BI reports »

Tesla had to rework over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TJX

TJX

$106.14

4.46 (4.39%)

11:21
08/21/18
08/21
11:21
08/21/18
11:21
Earnings
TJX sees Q3 revenue approximately $9.5B, consensus $9.31B »

Expects wage increases to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TJX

TJX

$105.94

4.26 (4.19%)

11:19
08/21/18
08/21
11:19
08/21/18
11:19
Earnings
TJX raises FY19 revenue view to $38.2B-$38.4B from $37.7B-$37.9B, consensus $38B »

Still expects pretax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TOL

Toll Brothers

$38.82

4.1 (11.81%)

11:18
08/21/18
08/21
11:18
08/21/18
11:18
Hot Stocks
Breaking Hot Stocks news story on Toll Brothers »

Toll Brothers sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

STLR

Stellar Acquisition III

$10.50

(0.00%)

11:17
08/21/18
08/21
11:17
08/21/18
11:17
Conference/Events
Stellar Acquisition III to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
08/21/18
08/21
11:17
08/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$39.13

4.41 (12.70%)

11:16
08/21/18
08/21
11:16
08/21/18
11:16
Hot Stocks
Breaking Hot Stocks news story on Toll Brothers »

Toll Brothers sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
08/21/18
08/21
11:16
08/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
08/21/18
08/21
11:15
08/21/18
11:15
General news
Breaking General news story  »

Week of 8/21 4-Week Bill…

DISCA

Discovery

$28.83

0.91 (3.26%)

, AAPL

Apple

$214.78

-0.7 (-0.32%)

11:13
08/21/18
08/21
11:13
08/21/18
11:13
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

DISCA

Discovery

$28.83

0.91 (3.26%)

AAPL

Apple

$214.78

-0.7 (-0.32%)

MSG

Madison Square Garden

$301.39

4.17 (1.40%)

MSGN

MSG Networks

$25.15

0.3 (1.21%)

TSLA

Tesla

$319.25

10.75 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TOL

Toll Brothers

$39.20

4.48 (12.90%)

11:13
08/21/18
08/21
11:13
08/21/18
11:13
Hot Stocks
Toll Brothers says current backlog gives good visibility through 1H19 »

The company projects FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

NFLX

Netflix

$339.01

11.26 (3.44%)

, AAPL

Apple

$214.71

-0.77 (-0.36%)

11:10
08/21/18
08/21
11:10
08/21/18
11:10
Hot Stocks
Analyst sees favorable setup ahead for Netflix on international subscriptions »

In a research note this…

NFLX

Netflix

$339.01

11.26 (3.44%)

AAPL

Apple

$214.71

-0.77 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

ROST

Ross Stores

$92.32

-0.01 (-0.01%)

11:10
08/21/18
08/21
11:10
08/21/18
11:10
Options
Defensive option play opened in Ross Stores ahead of earnings »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

11:10
08/21/18
08/21
11:10
08/21/18
11:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

TJX

TJX

$105.50

3.82 (3.76%)

11:09
08/21/18
08/21
11:09
08/21/18
11:09
Hot Stocks
Breaking Hot Stocks news story on TJX »

TJX still sees buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

DISCA

Discovery

$28.80

0.88 (3.15%)

, AAPL

Apple

$214.70

-0.78 (-0.36%)

11:09
08/21/18
08/21
11:09
08/21/18
11:09
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

DISCA

Discovery

$28.80

0.88 (3.15%)

AAPL

Apple

$214.70

-0.78 (-0.36%)

MSG

Madison Square Garden

$301.58

4.36 (1.47%)

MSGN

MSG Networks

$25.15

0.3 (1.21%)

TSLA

Tesla

$318.95

10.45 (3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TJX

TJX

$105.65

3.97 (3.90%)

11:05
08/21/18
08/21
11:05
08/21/18
11:05
Hot Stocks
TJX CEO Ernie Herrman says Q3 'off to a very strong start' »

Comment taken from the Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

PAYX

Paychex

$72.53

0.21 (0.29%)

11:00
08/21/18
08/21
11:00
08/21/18
11:00
Options
Paychex calls active »

Paychex calls active.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NVDA

Nvidia

$251.67

3.82 (1.54%)

, BIDU

Baidu

$225.00

1.37 (0.61%)

10:57
08/21/18
08/21
10:57
08/21/18
10:57
Hot Stocks
Citron remains cautious on Nvidia, repeats $200 per share forecast »

In a newly published…

NVDA

Nvidia

$251.67

3.82 (1.54%)

BIDU

Baidu

$225.00

1.37 (0.61%)

BABA

Alibaba

$178.80

2.59 (1.47%)

TCEHY

Tencent

$0.00

(0.00%)

FB

Facebook

$173.87

1.37 (0.79%)

GOOG

Alphabet

$1,215.21

7.67 (0.64%)

GOOGL

Alphabet Class A

$1,230.17

8.99 (0.74%)

MSFT

Microsoft

$106.99

0.12 (0.11%)

AMZN

Amazon.com

$1,891.43

15.98 (0.85%)

NFLX

Netflix

$338.51

10.76 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 10

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

DWDP

DowDuPont

$69.29

0.81 (1.18%)

10:50
08/21/18
08/21
10:50
08/21/18
10:50
Options
DowDuPont draws call buyers as shares see strength »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

XXII

22nd Century

$2.36

0.08 (3.51%)

10:42
08/21/18
08/21
10:42
08/21/18
10:42
Hot Stocks
22nd Century reports order for 3.6M SPECTRUM research cigarette »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.61

1.11 (0.64%)

10:41
08/21/18
08/21
10:41
08/21/18
10:41
Periodicals
Facebook is rating the trustworthiness of its users, Washington Post reports »

Facebook has started to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

AMTD

TD Ameritrade

$56.56

-3.6 (-5.98%)

10:40
08/21/18
08/21
10:40
08/21/18
10:40
Options
Heavy trading in TD Ameritrade as the stock comes under fire »

Heavy trading in TD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$21.09

0.57 (2.78%)

10:30
08/21/18
08/21
10:30
08/21/18
10:30
Options
Notable put buying in Uniti Group »

Notable put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$42.71

-0.01 (-0.02%)

10:29
08/21/18
08/21
10:29
08/21/18
10:29
Rumors
Rumor moving shares of Papa John's »

Rumor: Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.